Blog

NaviFUS Reports Breakthrough in U.S. Epilepsy Trial, Strengthens Global Footprint

NaviFUS Corps. (6872) announced that the U.S. clinical trial of its NaviFUS® focused ultrasound system for drug-resistant epilepsy (DRE), led by Stanford University successfully completed treatment of its first patient at the middle of Aug. The trial is expected to finish enrollment of all six participants in the first half of next year.

Focused Ultrasound for Epilepsy: Clinical Trial Begins in Australia

Key Points:
-The study is testing NaviFUS’s neuronavigation-guided focused ultrasound system for treating patients with drug-resistant epilepsy.
-Up to 18 participants will be treated in Melbourne.

NaviFUS Corp. Leverages Taiwan’s Advanced Chip Technology to Lead Non-Invasive Precision Medicine for Brain Disorders

NaviFUS Corp. is revolutionizing brain disorder treatments through ultrasound-based solutions, leveraging Taiwan’s advanced chip technology. By integrating ICT capabilities into high-end medical devices, NaviFUS enhances signal processing beyond traditional medical devices, positioning itself as a global leader in focused ultrasound treatments.

Exciting Partnership: NaviFUS and Bracco Join Forces to Revolutionize Brain Disease Treatment!

In April, NaviFUS entered into a cooperation agreement with Bracco, a global leader in ultrasound imaging agents, to enhance the NaviFUS® System’s capability to open the blood-brain barrier (BBB) for the treatment of brain cancers and neurological diseases. This year, the system will be tested in several clinical trials, marking a significant advancement in non-invasive therapies.

NaviFUS and Bracco Sign Cooperation Agreement for Precision FUS Treatment

NaviFUS (6872) and Bracco, the world’s leading brand of ultrasound imaging agents, officially signed a cooperation agreement recently (4/26). Bracco will provide its microbubble imaging agents as part of the NaviFUS system’s treatment to open the blood-brain barrier (BBB). As a technology platform, the NaviFUS System will be used in clinical trials of various brain cancers or neurological diseases and registrations for the treatment. It is expected that after obtaining the marketing authorization, Bracco will be responsible for supplying this microbubble OEM product and authorize NaviFUS to bundle it as a medical device consumable with its device for acoustic therapy sales.

Interview with Dr. Kuo-Chen Wei on Netflix K-Drama “Queen of Tears”: Taiwan’s NaviFUS FUS Technology Spearheading Revolutionary Treatment for Glioblastoma

“Queen of Tears,” a recent popular Netflix K-Drama has been captivating global audiences with the tumultuous romance between its two main leads. It also happens to feature a look into some real innovative medical advancements in the treatment of brain tumors. The focused ultrasound treatment Hong Hae-in (Kim Ji-won) receives for her glioblastoma has been utilized in Taiwanese medtech firm NaviFUS’ clinical trials for the last few years and highlights Taiwan’s role as a leader in focused ultrasound advancements for the treatment of brain cancer.

First Participant Receives Sonodynamic Therapy for Glioblastoma in New Clinical Trial

Key Points:
– A new clinical trial is investigating sonodynamic therapy for patients with recurrent glioblastoma.
– This is the first clinical trial in the US to use the NaviFUS device, which combines neuronavigation with a mobile, noninvasive focused ultrasound system.

NaviFUS completes innovative pilot study investigating FUS and re-radiotherapy combination treatment for recurrent glioblastoma tumors

NaviFUS Corporation is excited to announce that it recently received approval by the United States Food and Drug Administration (FDA) for an investigational device exemption (IDE) clinical trial using its NaviFUS® System focused ultrasound (FUS) device. The pilot-early feasibility study will be conducted at University of Virginia and will evaluate the combined effect of using the NaviFUS System® to open the blood-brain-barrier (BBB) and bevacizumab (Avastin®) drug treatment in rGBM patients.

NaviFUS completes innovative pilot study investigating FUS and re-radiotherapy combination treatment for recurrent glioblastoma tumors

NaviFUS’ research on combining focused ultrasound (FUS) with re-radiotherapy for the treatment of recurrent glioblatoma (rGBM) tumors has shown quite some promise in its recent clinical trial, and both the preliminary clinical results and previous preclinical data have been published in the Journal of Neuro-Oncology

Interview with 2023 TIE Award Winner NaviFUS CEO Arthur Lung

The NaviFUS System developed by NaviFUS Corp. was a winner of the TIE Award during Taiwan Innotech Expo this year. The device plans to complete a multi-national Phase III clinical trial, so the company is seeking to cooperate with major pharmaceuticals companies worldwide in testing their drugs or acquiring funding to obtain a sales license from the Ministry of Health and Welfare. Furthermore, the equipment needs specialized semiconductor components and microprocessors to generate and receive ultrasound. Hence, the company is searching for industry partners to engage in joint R&D to make the equipment smaller, so that patients will not need to go to a hospital and can use the equipment in a clinic or even at home.